LUGANO, 17 November 2017 - Just one in five Indonesian women are aware of cervical cancer screening, according to a study presented at the ESMO Asia 2017 Congress. (1) The research in nearly 5,400 women also found that only 5% knew about mammography for early detection of breast cancer.
"Early detection of cervical and breast cancers leads to better treatment, with improved survival and quality of life," said lead author Dr Sumadi Lukman Anwar, oncologist in training, Gadjah Mada University and Dr. Sardjito General Hospital, Yogyakarta, Indonesia.
"In Indonesia, many patients are diagnosed with breast and cervical cancers at a very late stage when there are limited options for curative treatment," he continued. "To improve early detection we need to know levels of awareness and participation in screening programmes, and what factors influence these levels."
Since 2015, all women in Indonesia aged 40 and above are eligible for cervical and breast cancer screening in primary healthcare funded by the Indonesian Ministry of Health (PERMENKES No.15/2015). Cervical smears are performed yearly for two years, then every five years if no abnormalities are found (otherwise they continue yearly). Clinical breast examinations are performed yearly and women are referred for sonography or mammography if there are any lumps or other signs of breast cancer. Women do not receive a letter inviting them to attend screening; in most cases they use their own initiative and ask for an appointment in primary healthcare.
The researchers assessed levels of awareness and participation in screening programmes for cervical and breast cancers. They also investigated factors that might influence these levels. The study used data from the Indonesian Family Life Survey (IFLS) which includes more than 30,000 individuals. (2) The first survey in 1993 was representative of 83% of the Indonesian population living in 13 of the 27 provinces in the country.
The current study is a collaborative work led by PILAR Research and Education and Gadjah Mada University and involves researchers from University College London, King's College London and University of Manchester. The analysis included 5,397 women aged 40 and older with no history of cancer who took part in the fifth IFLS survey, conducted in 2014 and 2015. Participants completed questionnaires about awareness and participation in cervical screening, mammography and breast self-examination. Information was also collected on factors that might be linked with cancer screening awareness and participation such as marital status, education, household expenditure, lifestyle, and distance to health facilities.
The researchers calculated the levels of awareness and participation in screening, and whether they varied by any of the population characteristics.
Only 1,058 (20%) of women were aware of cervical smears. Of those who were aware, only 297 women had ever had a cervical smear performed. Just 251 (5%) of women were aware of mammography and of those, only five women had received a mammogram in the previous year. Some 12% of women had done breast self-examination in the past year.
Higher education and household expenditure were associated with greater awareness of cervical smears and mammography, and greater participation in cervical smears and breast self-examination. Awareness and participation in screening was greater in those with health insurance, a shorter distance to health services, and who took part in community activities.
Anwar said: "We found very low levels of awareness of screening programmes for cervical and breast cancers in Indonesian women, and participation was even lower with indications of a social gradient. Health practitioners need to be aware of subgroups of women at risk who may benefit from improved information and communication concerning the availability of cancer screening. If further research supports the role of social participation, a campaign may be needed that is socially and culturally adapted for women in Indonesia and communicated using existing community networks and media they frequently use. Most people own mobile phones so the potential use of social media could also be explored."
Dr Wen-son Hsieh, Medical Oncologist, ICON-SOC and Farrer Park Hospital, Singapore said: "Cervical cancer is the 4th most common cancer in women worldwide and 8% of the cases occur in the developing world. This is at least partly due to the low incidence of screening procedures being performed in the developing world."
"The results of this study reinforce the concept that cancer screening programs can improve cancer screening rates in two ways: provide education resulting in improved awareness of the benefits of cancer screening and provide access to resources and facilities to allow cancer screening to occur."
Commenting on the study, Jonathan Ledermann, Professor of Medical Oncology, UCL Cancer Institute, London, UK, said: "The rates of awareness and uptake of screening for cervical and breast cancer found in this Indonesian study were extremely low compared to Western Europe where we would expect a 70% uptake. A better understanding is needed as to why these rates are so low."
"The clear message is that education about screening is not well disseminated amongst the population and uptake is even lower," he continued. "So there's a lot of work to be done, and a lot of investment that needs to be made in education and facilities for screening if Indonesia is going to climb up the ladder of screening for those two cancers."
Notes to Editors
Please make sure to use the official name of the meeting in your reports: ESMO Asia 2017 Congress
References and note
(1) Abstract 288O_PR 'Determinants of cancer screening awareness and participation among Indonesian women: A nationwide study' will be presented by Sumadi Lukman Anwar during the Mini Oral session on gynaecological cancers on Saturday, 18 November 2017, 16:30 to 17:15 (SGT) in Hall 407. Annals of Oncology, Volume 28, 2017 Supplement 10.
(2) The Indonesia Family Life Survey (IFLS): https:/
This press release contains information provided by the authors of the highlighted abstracts and reflects the content of those abstracts. It does not necessarily reflect the views or opinions of ESMO who cannot be held responsible for the accuracy of the data. Commentators quoted in the press release are required to comply with the ESMO Declaration of Interests policy and the ESMO Code of Conduct.
About the European Society for Medical Oncology (ESMO)
ESMO is the leading professional organisation for medical oncology. With 17,000 members representing oncology professionals from 150 countries worldwide, ESMO is the society of reference for oncology education and information. We are committed to supporting our members to develop and advance in a fast-evolving professional environment.